Top Stories

The Personalized Medicine Foundation (PMF) a leading cancer patient advocacy organization focused on patient education

Alcensa, Xalkori, and several other precision cancer medicines target ALK positive lung cancer and improve treatment.

Cancer diagnoses drop as many skip screening due to COVID-19. COVID may lead to 10,000 excess cancer deaths

Lobrena - a third generation ALK inhibitor drug with excellent CNS activity

The COVID-19 pandemic is creating a new normal-patients need to adapt to reduce risk and understand treatment decisions.

3D Bioprinting is and innovative approach to provide a revolutionized personal treatment plan for cancer patients

The sudden, rapid death of cancer cells in response to cancer treatment causes metabolic and electrolyte disturbances.

Genomic testing identifies targets that can be treated with precision cancer medicines. ASCO 2020 update